[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 18.206.194.83. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Viewpoint
January 2017

Drug Price Inflation and the Cost of Assisted Death for Terminally Ill Patients—Death With Indignity

Author Affiliations
  • 1Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington
  • 2Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
  • 3Division of Medical Oncology, University of Washington School of Medicine, Seattle
  • 4Department of Pharmacy, Seattle Cancer Care Alliance, Seattle, Washington
JAMA Oncol. 2017;3(1):15-16. doi:10.1001/jamaoncol.2016.3842

The Washington State Death with Dignity (DWD) Act passed into law in November 2008 and allows terminally ill adults with a life expectancy of fewer than 6 months to request lethal doses of barbiturate medications to end their lives. Participants have cited concerns about loss of autonomy, dignity, and ability to engage in activities that make life enjoyable as reasons for participating in the program.1,2 Since 2009, the number of DWD prescriptions dispensed in Washington State has steadily increased, and the majority of patients (approximately 75% with cancer diagnoses) to whom the medications are dispensed will ingest them.1 The DWD program has generally been considered successful and patients have reported feeling grateful to have an option for physician-assisted death.2 Today, however, patients and their families are raising new concerns about the high cost of DWD medication and the unaffordability of ending their lives in this way.

×